TI
NGNE icon

Trexquant Investment’s Neurogene NGNE Stock Holding History

Trexquant Investment’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-43,323
Closed -$892K – 1956
2025
Q4 		$892K Buy
43,323
+3,840
+10% +$95.6K 0.01% 1215
2025
Q3 		$684K Buy
+39,483
New +$793K 0.01% 1252
2022
Q1 		– Sell
-2,436
Closed -$235K – 1613
2021
Q4 		$235K Buy
2,436
+721
+42% +$87.8K 0.01% 1054
2021
Q3 		$248K Buy
1,715
+1,004
+141% +$154K 0.02% 851
2021
Q2 		$131K Buy
+711
New +$157K 0.01% 990
2021
Q1 		– Sell
-607
Closed -$171K – 1350
2020
Q4 		$171K Buy
+607
New +$148K 0.02% 919

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Trexquant Investment's NGNE Position: Q1 2026 in Review

Trexquant Investment sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 43,323 shares — an estimated $892K sold.

Trexquant Investment first reported a position in NGNE in Q4 2020 and held it in 6 quarters. The position peaked at $892K in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Trexquant Investment reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Trexquant Investment sold 43,323 Neurogene shares in Q1 2026, an estimated $892K.
  • Trexquant Investment first reported a position in Neurogene in Q4 2020 and held it in 6 quarters.
  • Trexquant Investment's Neurogene position peaked at $892K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.